Cancer Patients With Diabetes May Have Worse Outcomes on ICIs
Cancer patients with type 2 diabetes may have worse survival outcomes on immune checkpoint inhibitor therapy, a new study suggests.
Diagnosis & Disease Information
Blood Type Associated With Immunotherapy Outcomes in RCC
Blood type may impact immunotherapy outcomes in patients with metastatic RCC, a study suggests.
Avelumab Plus Cabozantinib Appears Safe, Active in Metastatic Clear Cell RCC
Avelumab plus cabozantinib has shown preliminary clinical activity and an acceptable safety profile in metastatic clear cell RCC, according to researchers.
Could Mean Platelet Volume Serve as a Prognostic Indicator for Outcomes in Cancer?
Researchers sought to determine the predictive value of mean platelet volume as a marker for cancer outcomes.
Researchers Identify Genetic Correlations Across Cancer Types
Researchers have identified 15 novel loci associated with cancer and discovered genetic correlations across different cancer types.
Benefits Persist for Lenvatinib, Pembrolizumab in Renal Cell Cancer
Updated analysis showed longer progression-free and overall survival for patients with advanced renal cell carcinoma.
Partial Cytoreductive Nephrectomy Still Offers Survival Edge in Metastatic RCC
In a study, partial vs radical cytoreductive nephrectomy for clear cell metastatic renal cell carcinoma was associated with a 54% decreased risk for other-cause mortality.
New Treatments, New Challenges in the Treatment of Bladder and Renal Cancers
A discussion of new treatment options that have improved prognosis for patients with bladder cancer and renal cell carcinoma is the focus of a presentation at the 2023 ONA Summit.
Identifying and Managing Adverse Reactions to Lenvatinib and Pembrolizumab
Researchers have characterized common adverse reactions to combination lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma.
Health-Related QOL Outcomes Superior With Higher Lenvatinib Starting Dose in RCC
Researchers randomly assigned patients with RCC to receive 18 mg or 14 mg of lenvatinib plus 5 mg everolimus to determine which produced better HRQOL.
- Loading...
Loading...
Next post in Kidney Cancer
Loading... 
Loading...